Teva offers to acquire Mylan for $40.1bn
Teva has offered $82 for each Mylan share in this cash and stock deal, which is expected to transform the generic drugs industry. According to Teva, the proposal
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted paediatric clinical trial waivers to Shanton Pharma for its lead candidate SAP-001, easing the drug’s regulatory paths to approval.
Minocin for Injection is a tetracycline derivative approved in the US to treat infections due to susceptible strains of several important designated gram-positive and gram-negative pathogens, including infections
The randomized, double-blind, multicenter, placebo-controlled (2:1) MS-SPI trial evaluated the efficacy and safety of MD1003, 300mg/day, in patients with progressive MS who have showed progression in the two